Canakinumab allows discontinuation of corticosteroids in patients with SJIA EurekAlert (press release) Madrid, Spain, 13 June 2013: Study findings first presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate the efficacy of canakinumab at tapering corticosteroid (CS) use in patients with SJIA. |
